Skip to main content
Top
Published in: Indian Journal of Gastroenterology 6/2016

01-11-2016 | Original Article

Chronic hepatitis C virus infection in India: Regional demographics and distribution of viral genotypes

Authors: Samir R. Shah, P. N. Rao, Shiv K. Sarin, Abhijit Chowdhury, Shobna Bhatia, Rajesh Dharamsi, B. D. Goswami, Dharmesh Kapoor, Rosang Luaia, Rajiv Mehta, Shrikant Mukewar, V. G. Mohan Prasad, Ramesh Roop Rai, Sanjiv Saigal, Devendra Singh, Nirupama Trehanpati, Sandra Chen, Anuj Gaggar, Steven J. Knox, G. Mani Subramanian, Shivaram Prasad Singh, Ajit Sood, Joy Varghese, Raj Vigna Venugopal

Published in: Indian Journal of Gastroenterology | Issue 6/2016

Login to get access

Abstract

Background and Aims

Although chronic hepatitis C virus (HCV) infection affects millions of people in India, few studies have assessed host, viral, and disease characteristics of chronically infected patients at national and regional levels. Such information is critical to support large scale screening and treatment initiatives for chronic HCV infection in India.

Methods

Patients with known chronic HCV infection making routine or for-cause visits to the participating study centers were enrolled in this observational study. Patients attended a single outpatient visit during which demographics and medical history were collected, a physical examination was performed, and blood and urine samples were collected for laboratory assessments. Samples were analyzed to determine HCV genotypes and subtypes, and genotypes of interferon lambda 3 (IFNL3) single nucleotide polymorphism. No therapeutic interventions were administered.

Results

We enrolled 500 patients at 19 centers, categorized into four geographic regions (North, South, East, and West). All patients self-identified as Indian, and most (66 %) were male. Genotype 3 was the most common genotype overall (54 %); however, its prevalence varied greatly by region, ranging from 34 % in the South to 69 % in the East. Genotypes 1 (24 %) and 4 (6 %) were the next most common, and HCV genotype could not be determined for 16 % of patients.

Conclusions

This prospective survey suggests that demographics, viral, and host factors in patients with chronic HCV infection are highly variable in India and pose significant challenges for the implementation of broad-scale screening and treatment initiatives.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011;31 Suppl 2:61–80.CrossRefPubMed Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011;31 Suppl 2:61–80.CrossRefPubMed
2.
go back to reference Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333–42.CrossRefPubMed Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333–42.CrossRefPubMed
3.
go back to reference Saravanan S, Velu V, Kumarasamy N, et al. The prevalence of hepatitis B virus and hepatitis C virus infection among patients with chronic liver disease in South India. Int J Infect Dis. 2008;12:513–8.CrossRefPubMed Saravanan S, Velu V, Kumarasamy N, et al. The prevalence of hepatitis B virus and hepatitis C virus infection among patients with chronic liver disease in South India. Int J Infect Dis. 2008;12:513–8.CrossRefPubMed
4.
go back to reference Hatzakis A, Chulanov V, Gadano AC, et al. The present and future disease burden of hepatitis C virus (HCV) infections with today’s treatment paradigm—volume 2. J Viral Hepatol. 2015;22:26–45.CrossRef Hatzakis A, Chulanov V, Gadano AC, et al. The present and future disease burden of hepatitis C virus (HCV) infections with today’s treatment paradigm—volume 2. J Viral Hepatol. 2015;22:26–45.CrossRef
5.
go back to reference Tamayo A, Shah SR, Bhatia S, et al. Correlates of disease-specific knowledge among patients with chronic hepatitis B or hepatitis C infection in India. Hepatol Int. 2016;10:988-995. Tamayo A, Shah SR, Bhatia S, et al. Correlates of disease-specific knowledge among patients with chronic hepatitis B or hepatitis C infection in India. Hepatol Int. 2016;10:988-995.
6.
go back to reference Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401.CrossRefPubMed Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401.CrossRefPubMed
7.
go back to reference Nakano T, Lau GM, Sugiyama M, Mizokami M. An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding regions. Liver Int. 2012;32:339–45.CrossRefPubMed Nakano T, Lau GM, Sugiyama M, Mizokami M. An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding regions. Liver Int. 2012;32:339–45.CrossRefPubMed
8.
go back to reference Antaki N, Craxi A, Kamal S, et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int. 2010;30:342–55.CrossRefPubMed Antaki N, Craxi A, Kamal S, et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int. 2010;30:342–55.CrossRefPubMed
9.
go back to reference Kaur H, Singh P, Pannu HS, Sood A, Jain NP, Bhoday HS. To study the prevalence of impaired glucose tolerance in patients with hepatitis C virus related chronic liver disease. J Clin Diagn Res. 2015;9:OC16–20.PubMedPubMedCentral Kaur H, Singh P, Pannu HS, Sood A, Jain NP, Bhoday HS. To study the prevalence of impaired glucose tolerance in patients with hepatitis C virus related chronic liver disease. J Clin Diagn Res. 2015;9:OC16–20.PubMedPubMedCentral
10.
go back to reference Pastore F, Martocchia A, Stefanelli M, et al. Hepatitis C virus infection and thyroid autoimmune disorders: a model of interactions between the host and the environment. World J Hepatol. 2016;8:83–91.CrossRefPubMedPubMedCentral Pastore F, Martocchia A, Stefanelli M, et al. Hepatitis C virus infection and thyroid autoimmune disorders: a model of interactions between the host and the environment. World J Hepatol. 2016;8:83–91.CrossRefPubMedPubMedCentral
11.
go back to reference Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005;128:636–41.CrossRefPubMed Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005;128:636–41.CrossRefPubMed
12.
go back to reference Eslam M, Aparcero R, Kawaguchi T, et al. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther. 2011;34:297–305.CrossRefPubMed Eslam M, Aparcero R, Kawaguchi T, et al. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther. 2011;34:297–305.CrossRefPubMed
Metadata
Title
Chronic hepatitis C virus infection in India: Regional demographics and distribution of viral genotypes
Authors
Samir R. Shah
P. N. Rao
Shiv K. Sarin
Abhijit Chowdhury
Shobna Bhatia
Rajesh Dharamsi
B. D. Goswami
Dharmesh Kapoor
Rosang Luaia
Rajiv Mehta
Shrikant Mukewar
V. G. Mohan Prasad
Ramesh Roop Rai
Sanjiv Saigal
Devendra Singh
Nirupama Trehanpati
Sandra Chen
Anuj Gaggar
Steven J. Knox
G. Mani Subramanian
Shivaram Prasad Singh
Ajit Sood
Joy Varghese
Raj Vigna Venugopal
Publication date
01-11-2016
Publisher
Springer India
Published in
Indian Journal of Gastroenterology / Issue 6/2016
Print ISSN: 0254-8860
Electronic ISSN: 0975-0711
DOI
https://doi.org/10.1007/s12664-016-0709-1

Other articles of this Issue 6/2016

Indian Journal of Gastroenterology 6/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.